{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:37:08Z","timestamp":1789040228612,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s15010-024-02174-4","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T10:02:10Z","timestamp":1707213730000},"page":"707-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"52","author":[{"given":"Mohamed T.","family":"Abuelazm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elzeftawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar Ahmed","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmy","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aboulgheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherief","family":"Abd-elsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2174_CR1","unstructured":"Malaria vaccines: preferred product characteristics and clinical development considerations. https:\/\/www.who.int\/publications-detail-redirect\/9789240057463. Accessed 10 Nov 2023."},{"key":"2174_CR2","unstructured":"Autoridad Nacional del Servicio Civil. World malaria report 2021. Angewandte Chemie International Edition, 6(11), 951\u2013952. 2021;2013\u20135."},{"key":"2174_CR3","volume-title":"Malaria","author":"World Health Organization (WHO)","year":"2021","unstructured":"World Health Organization (WHO). Malaria. Geneva: World Health Organization; 2021."},{"key":"2174_CR4","first-page":"1","volume-title":"World malaria report 2019","author":"WHO Global","year":"2019","unstructured":"WHO Global. World malaria report 2019. Brazzaville: WHO Regional Office for Africa; 2019. p. 1\u2013232."},{"key":"2174_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok Z, Fendel R, Eder B, Lorenz FR, Kc N, Karnahl M, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12:1\u201310.","journal-title":"Nat Commun"},{"key":"2174_CR6","first-page":"1","volume":"2019","author":"J Zheng","year":"2019","unstructured":"Zheng J, Pan H, Gu Y, Zuo X, Ran N, Yuan Y, et al. Prospects for malaria vaccines: pre-erythrocytic stages, blood stages, and transmission-blocking stages. BioMed Res Int. 2019;2019:1.","journal-title":"BioMed Res Int"},{"key":"2174_CR7","first-page":"1","volume-title":"Global technical strategy for malaria 2016\u20132030, 2021 update","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global technical strategy for malaria 2016\u20132030, 2021 update. Geneva: World Health Organization; 2021. p. 1\u201340."},{"key":"2174_CR8","doi-asserted-by":"publisher","first-page":"e50464","DOI":"10.1371\/journal.pone.0050464","volume":"7","author":"V Choumet","year":"2012","unstructured":"Choumet V, Attout T, Chartier L, Khun H, Sautereau J, Robbe-Vincent A, et al. Visualizing non infectious and infectious anopheles gambiae blood feedings in naive and saliva-immunized mice. PLoS ONE. 2012;7:e50464. https:\/\/doi.org\/10.1371\/journal.pone.0050464.","journal-title":"PLoS ONE"},{"key":"2174_CR9","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","volume":"33","author":"SL Hoffman","year":"2015","unstructured":"Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Vaccine. 2015;33:D13-23.","journal-title":"Vaccine"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1586\/erv.12.92","volume":"11","author":"PE Duffy","year":"2012","unstructured":"Duffy PE, Sahu T, Akue A, Milman N, Anderson C. Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines. 2012;11:1261\u201380.","journal-title":"Expert Rev Vaccines"},{"key":"2174_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"2174_CR12","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA. 2017;114:2711\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/infdis\/jiu063","volume":"209","author":"M Spring","year":"2014","unstructured":"Spring M, Polhemus M, Ockenhouse C. Controlled human malaria infection. J Infect Dis. 2014;209:S40\u20135.","journal-title":"J Infect Dis"},{"key":"2174_CR14","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583.","journal-title":"PLoS Med"},{"key":"2174_CR15","unstructured":"Innovation VH. Covidence systematic review software. Melbourne, Australia."},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2174_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. Rating quality of evidence and strength of recommendations: what is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ Br Med J. 2008;336:995.","journal-title":"BMJ Br Med J"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ Br Med J. 2008;336:924.","journal-title":"BMJ Br Med J"},{"key":"2174_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327:557.","journal-title":"BMJ Br Med J"},{"key":"2174_CR20","unstructured":"RevMan | Cochrane Training. https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman. Accessed 3 Aug 2021."},{"key":"2174_CR21","unstructured":"MedCalc\u00ae Statistical Software version 20.027 (MedCalc Software Ltd, Ostend, Belgium. 2022. https:\/\/www.medcalc.org"},{"key":"2174_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557\u201360.","journal-title":"Br Med J"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"2174_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"2174_CR25","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo SA, Preston Church LW, Mtoro AT, Schindler T, Chakravarty S, Ruben AJ, et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian Adults. Clin Infect Dis. 2020;71:2849\u201357.","journal-title":"Clin Infect Dis"},{"key":"2174_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciz925","volume":"71","author":"LC Steinhardt","year":"2020","unstructured":"Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, et al. Safety, tolerability, and immunogenicity of plasmodium falciparum sporozoite vaccine administered by direct venous inoculation to infants and young children: Findings from an age de-escalation, dose-escalation, double-blind, randomized controlled study in. Clin Infect Dis. 2020;71:1063\u201371.","journal-title":"Clin Infect Dis"},{"key":"2174_CR27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and differential antibody and T-cell responses to the plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019;100:1433\u201344.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of pfspz vaccine for malaria in healthy equatoguinean men. Am J Trop Med Hyg. 2018;98:308\u201318.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalaghe SA, Preston Church LW, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99:338\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2022","unstructured":"Sissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis. 2022;22:377\u201389.","journal-title":"Lancet Infect Dis"},{"key":"2174_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","volume":"104","author":"SA Jongo","year":"2021","unstructured":"Jongo SA, Urbano V, Preston Church LW, Olotu A, Manock SR, Schindler T, et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in equatoguinean adults. Am J Trop Med Hyg. 2021;104:283\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy SC, Deye GA, Kim Lee Sim B, Galbiati S, Kennedy JK, Cohen KW, et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 2021;17:1\u201323.","journal-title":"PLoS Pathog"},{"key":"2174_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017;2:1\u201314.","journal-title":"JCI Insight"},{"key":"2174_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595:289\u201394.","journal-title":"Nature"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, et al. Multidose priming and delayed boosting improve Plasmodium falciparum Sporozoite vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin Infect Dis. 2021;73:e2424\u201335.","journal-title":"Clin Infect Dis"},{"key":"2174_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"2174_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614\u201323.","journal-title":"Nat Med"},{"key":"2174_CR38","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021;27:1636\u201345.","journal-title":"Nat Med"},{"key":"2174_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR40","doi-asserted-by":"publisher","first-page":"e71539","DOI":"10.1371\/journal.pone.0071539","volume":"8","author":"E Kamau","year":"2013","unstructured":"Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. Multiplex qPCR for detection and absolute quantification of malaria. PLoS ONE. 2013;8:e71539.","journal-title":"PLoS ONE"},{"key":"2174_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3389\/fimmu.2019.01227","volume":"10","author":"YS Goh","year":"2019","unstructured":"Goh YS, McGuire D, R\u00e9nia L. Vaccination with sporozoites: models and correlates of protection. Front Immunol. 2019;10:1227.","journal-title":"Front Immunol"},{"key":"2174_CR42","unstructured":"EMA. First malaria vaccine receives positive scientific opinion from EMA. European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/news\/first-malaria-vaccine-receives-positive-scientific-opinion-ema. Accessed 10 Nov 2023."},{"key":"2174_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2018.06.060","volume":"24","author":"MV Wagle","year":"2018","unstructured":"Wagle MV, Marchingo JM, Howitt J, Tan SS, Goodnow CC, Parish IA. The ubiquitin ligase adaptor NDFIP1 selectively enforces a CD8+ T cell tolerance checkpoint to high-dose antigen. Cell Rep. 2018;24:577\u201384.","journal-title":"Cell Rep"},{"key":"2174_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00475","author":"M Cornberg","year":"2013","unstructured":"Cornberg M, Kenney LL, Chen AT, Waggoner SN, Kim SK, Dienes HP, et al. Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response. Front Immunol. 2013. https:\/\/doi.org\/10.3389\/fimmu.2013.00475.","journal-title":"Front Immunol"},{"key":"2174_CR45","doi-asserted-by":"publisher","first-page":"20453","DOI":"10.1073\/pnas.1008437107","volume":"107","author":"S Han","year":"2010","unstructured":"Han S, Asoyan A, Rabenstein H, Nakano N, Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci USA. 2010;107:20453\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2174_CR46","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.4049\/jimmunol.172.9.5405","volume":"172","author":"M-C Michallet","year":"2004","unstructured":"Michallet M-C, Saltel F, Flacher M, Revillard J-P, Genestier L. Cathepsin-dependent apoptosis triggered by Supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance. J Immunol. 2004;172:5405\u201314.","journal-title":"J Immunol"},{"key":"2174_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1165\/ajrcmb.21.2.3576","volume":"21","author":"K Haneda","year":"1999","unstructured":"Haneda K, Sano K, Tamura G, Shirota H, Ohkawara Y, Sato T, et al. Transforming growth factor-\u03b2 secreted from CD4+ T cells ameliorates antigen-induced eosinophilic inflammation: a novel high-dose tolerance in the trachea. Am J Respir Cell Mol Biol. 1999;21:268\u201374.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2174_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0008-8749(95)80011-7","volume":"160","author":"JM Critchfield","year":"1995","unstructured":"Critchfield JM, Z\u00fa\u00f1iga-Pfl\u00fccker JC, Lenardo MJ. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell Immunol. 1995;160:71\u20138.","journal-title":"Cell Immunol"},{"key":"2174_CR49","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","volume":"49","author":"SL Hoffman","year":"2015","unstructured":"Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Am J Prev Med. 2015;49:S319\u201333.","journal-title":"Am J Prev Med"},{"key":"2174_CR50","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie TL, Billingsley PF, Sim BKL, James ER, Chakravarty S, Epstein JE, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33:7452\u201361.","journal-title":"Vaccine"},{"key":"2174_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4269\/ajtmh.22-0773","volume":"109","author":"SA Jongo","year":"2023","unstructured":"Jongo SA, Urbano Nsue Ndong Nchama V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Safety and immunogenicity of radiation-attenuated PfSPZ vaccine in equatoguinean infants, children, and adults. Am J Trop Med Hyg. 2023;109:138\u201346.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR52","doi-asserted-by":"publisher","first-page":"abj3776","DOI":"10.1126\/scitranslmed.abj3776","volume":"14","author":"SB Sirima","year":"2022","unstructured":"Sirima SB, Ou\u00e9draogo A, Tiono AB, Kabor\u00e9 JM, Bougouma EC, Ouattara MS, et al. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria. Sci Transl Med. 2022;14:abj3776. https:\/\/doi.org\/10.1126\/scitranslmed.abj3776.","journal-title":"Sci Transl Med"},{"key":"2174_CR53","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.vaccine.2012.10.109","volume":"31","author":"CR Garcia","year":"2013","unstructured":"Garcia CR, Manzi F, Tediosi F, Hoffman SL, James ER. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine. 2013;31:380\u20136.","journal-title":"Vaccine"},{"key":"2174_CR54","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.eclinm.2022.101579","volume":"52","author":"D Coulibaly","year":"2022","unstructured":"Coulibaly D, Kone AK, Traore K, Niangaly A, Kouriba B, Arama C, et al. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: a randomized, controlled phase 1 trial. EClinicalMedicine. 2022;52:101579.","journal-title":"EClinicalMedicine"},{"key":"2174_CR55","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.21-0942","volume":"106","author":"SA Jongo","year":"2022","unstructured":"Jongo SA, Church LWP, Nchama VUNN, Hamad A, Chuquiyauri R, Kassim KR, et al. Multi-dose priming regimens of PfSPZ vaccine: safety and efficacy against controlled human malaria infection in Equatoguinean adults. Am J Trop Med Hyg. 2022;106:1215\u201326.","journal-title":"Am J Trop Med Hyg"},{"key":"2174_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-022-00510-z","volume":"7","author":"B Mordm\u00fcller","year":"2022","unstructured":"Mordm\u00fcller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, et al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022;7:100.","journal-title":"NPJ Vaccines"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02174-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T18:35:05Z","timestamp":1717180505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02174-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02174-4","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}